• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary Disease.中重度慢性阻塞性肺疾病的三联疗法
CADTH Technol Overv. 2010;1(4):e0129. Epub 2010 Dec 1.
2
Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.吸入性皮质类固醇联合吸入长效β2-激动剂和长效抗胆碱能药物治疗慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2023 Dec 6;12(12):CD011600. doi: 10.1002/14651858.CD011600.pub3.
3
Efficacy and Safety of Single Inhaler Triple Therapy Versus Separate Triple Therapy in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis.单吸入器三联疗法与慢性阻塞性肺疾病中分别三联疗法的疗效和安全性：系统评价和荟萃分析。
Clin Ther. 2022 Jun;44(6):859-873. doi: 10.1016/j.clinthera.2022.04.004. Epub 2022 May 6.
4
Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.单吸入器三联疗法治疗慢性阻塞性肺疾病患者：系统评价。
Respir Res. 2019 Nov 4;20(1):242. doi: 10.1186/s12931-019-1213-9.
5
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.FULFIL 试验：慢性阻塞性肺疾病患者的每日一次三联疗法。
Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC.
6
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.血液嗜酸性粒细胞与慢性阻塞性肺疾病三联和双联治疗反应：IMPACT 试验分析。
Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4.
7
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.一项使用共悬浮递送技术的布地奈德/格隆溴铵/富马酸福莫特罗三药联合治疗中重度至极重度 COPD 的 III 期研究：ETHOS 研究方案。
Respir Med. 2019 Oct-Nov;158:59-66. doi: 10.1016/j.rmed.2019.08.010. Epub 2019 Aug 22.
8
Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline.吸入性皮质类固醇停药对基线接受三联治疗的慢性阻塞性肺疾病患者加重的影响。
Int J Chron Obstruct Pulmon Dis. 2020 Nov 11;15:2879-2888. doi: 10.2147/COPD.S237408. eCollection 2020.
9
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.慢性阻塞性肺疾病患者的长期三联疗法降级至茚达特罗/格隆溴铵（SUNSET）：一项随机、双盲、三盲临床试验。
Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-339. doi: 10.1164/rccm.201803-0405OC.
10
Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis.三联疗法治疗慢性阻塞性肺疾病的系统评价和荟萃分析。
BMJ. 2018 Nov 6;363:k4388. doi: 10.1136/bmj.k4388.

引用本文的文献

1
Initiation of triple therapy maintenance treatment among patients with COPD in the US.美国慢性阻塞性肺疾病患者三联疗法维持治疗的启动情况。
Int J Chron Obstruct Pulmon Dis. 2016 Dec 22;12:73-83. doi: 10.2147/COPD.S122013. eCollection 2017.
2
The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.慢性阻塞性肺疾病（COPD）三联疗法的必然趋势：英国处方途径分析
Int J Chron Obstruct Pulmon Dis. 2015 Oct 15;10:2207-17. doi: 10.2147/COPD.S91694. eCollection 2015.

本文引用的文献

1
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.在慢性阻塞性肺疾病患者中，噻托溴铵联合布地奈德/福莫特罗的疗效和耐受性。
Am J Respir Crit Care Med. 2009 Oct 15;180(8):741-50. doi: 10.1164/rccm.200904-0492OC. Epub 2009 Jul 30.
2
[Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].吸入用沙美特罗/氟替卡松与噻托溴铵联合治疗慢性阻塞性肺疾病：一项随机对照试验
Zhonghua Jie He He Hu Xi Za Zhi. 2008 Nov;31(11):811-4.
3
Outcomes for COPD pharmacological trials: from lung function to biomarkers.慢性阻塞性肺疾病（COPD）药物试验的结果：从肺功能到生物标志物
Eur Respir J. 2008 Feb;31(2):416-69. doi: 10.1183/09031936.00099306.
4
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update.加拿大胸科学会慢性阻塞性肺疾病管理建议——2007年更新版
Can Respir J. 2007 Sep;14 Suppl B(Suppl B):5B-32B. doi: 10.1155/2007/830570.
5
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.噻托溴铵联合安慰剂、沙美特罗或氟替卡松-沙美特罗治疗慢性阻塞性肺疾病：一项随机试验。
Ann Intern Med. 2007 Apr 17;146(8):545-55. doi: 10.7326/0003-4819-146-8-200704170-00152. Epub 2007 Feb 19.
6
A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.一项评估丙酸氟替卡松/沙美特罗与噻托溴铵联合使用对重度至极重度慢性阻塞性肺疾病（COPD）患者气流阻塞影响的初步研究。
Pulm Pharmacol Ther. 2007;20(5):556-61. doi: 10.1016/j.pupt.2006.06.001. Epub 2006 Jul 7.
7
State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease.最新技术纲要：加拿大胸科学会慢性阻塞性肺疾病管理指南
Can Respir J. 2004 Jul-Aug;11 Suppl B:7B-59B. doi: 10.1155/2004/946769.
8
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.慢性阻塞性肺疾病诊断、管理和预防全球策略。美国国立心肺血液研究所/世界卫生组织慢性阻塞性肺疾病全球倡议（GOLD）研讨会总结。
Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76. doi: 10.1164/ajrccm.163.5.2101039.
9
Airway inflammation in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中的气道炎症
Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 2):S17-20. doi: 10.1164/ajrccm.160.supplement_1.6.

Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary Disease.

出版信息

CADTH Technol Overv. 2010;1(4):e0129. Epub 2010 Dec 1.

PMID:22977419
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3411162/
Abstract
摘要